Past events & courses

In the footsteps of our previous joint meeting in 2017, BSOH and BBP again joined forces to organize an event. This year, we will focus on where and how the occupational hygienist and the biosafety coordinator can collaborate. By means of practical cases, the roles of both functions and the opportunities for collaboration will be highlighted.

The second of 5 online, member only, meetings in 2021 with Ursula Jenal and Toon De KeselEvery single document on biorisk management stresses the importance of a robust risk assessment. The fourth edition of the WHO Laboratory Biosafety Manual promotes the thorough, evidence-based and transparent assessment of the risks. ISO 35001 stipulates that an organization shall ensure that suitable methodologies for assessing and prioritizing biorisks are identified, implemented, maintained, and documented.

Organised by Dr. Felix Gmünder (Basler & Hofmann) and Fabio Blaha (German LabConCert GmbH)

Course completely in FrenchCours entièrement en français Ce cours est une introduction au sujet. Il décrit les approches les plus utilisées, en mettant l’accent sur les critères important à évaluer pour le choix d’une approche et la vérification de son efficacité.

RE-RUN UPON POPULAR DEMAND (confirmation as soon as we have 25 participants) In this webinar these and other questions will be addressed by using the risk based approach of the new WHO biosafety manual. 

The Symposium will consist of papers, presentations, keynotes, posters, valuable networking opportunities, and exhibits.

Digital symosium, free for all BBP and EBSA members.

The WHO Laboratory Biosafety Manual (LBM) serves as a de facto global standard that presents best practices and sets trends in biosafety. The recent publication of the fourth edition expands the thorough, evidence-based and transparent assessment of the risks, allowing safety measures to be balanced with the actual risk of working with biological agents on a case-by-case basis.  A challenging shift from routines based on levels? An opportunity to allow optimizing risk management, in particular in less resourced envrionments? Join us and discuss with two of the LBM4 contributors, active EBSA members, providing their insights on the (r)evolution this version marks and how biosafety professionals can use it in their daily practice.

February 18, 2021 12:00 - 1:30 pm (CST) Biosafety and the COVID-19 Vaccines is intended to provide an overview of the clinical trial development and biosafety considerations of the currently approved COVID-19 vaccines.